What's behind AstraZeneca's latest 9.1% stock pullback?

Traders Union
All News
Financial News
Astrazeneca slides 9.06% after trial miss

Highlights

AstraZeneca's late-stage eplontersen trial for transthyretin amyloid cardiomyopathy missed its primary endpoint, marking a significant pipeline setback.
The company secured a $2.1 billion licensing deal with Sino Biopharma and is negotiating broader NHS access to Enhertu in the UK.
Shares trade under key moving averages, intraday volatility is elevated at 5.81%, and the stock is forecast to consolidate within a GBX11,270–13,251 range despite mixed technical signals.

Investor sentiment shifts on trial miss and mixed partnership news

AstraZeneca reported a setback in its late-stage Wainua (eplontersen) clinical trial for transthyretin amyloid cardiomyopathy, developed in collaboration with Ionis Pharmaceuticals, as the study failed to meet its primary endpoint. The company also concluded several licensing and collaboration agreements, including a deal with Sino Biopharma worth up to $2.1 billion and new partnerships involving TQC3721 and Helix. AstraZeneca is nearing an agreement with UK regulators to broaden NHS access to Enhertu, its therapy for breast cancer, and officers were granted additional shares under the incentive plan.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca under significant pressure after the failed Wainua trial. He notes that the technical picture is bearish, with the price below all moving averages and persistent selling dominating recent sessions. The rebound off intraday lows does not yet signal a shift in trend as resistance levels remain intact. Kharitonov points to the mixed momentum signals and warns of ongoing uncertainty driven by weak fundamental results and negative sentiment. He concludes, "Unless the stock regains GBX13,107 soon, the downside risk remains elevated and buyers should stay cautious."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive stance despite the recent setback for AstraZeneca. He believes the company’s continued licensing deals and NHS agreement negotiations support a strong long-term outlook. Karapetjanc sees new partnerships and collaboration opportunities offsetting the negative news flow and keeping future growth prospects intact. "With momentum indicators mixed but consolidation likely, further growth remains possible as AstraZeneca leverages its broad pipeline," he states.

Bearish alignment persists as moving averages and momentum diverge

AZN is trading well below its MA-20 (GBX13,821), MA-50 (GBX13,731), and MA-200 (GBX13,768), indicating sustained pressure from sellers across short, medium, and long-term trends. The alignment of the MA-50 below the MA-200 reinforces the bearish outlook. Resistance is seen at GBX13,107 and support at GBX12,388, with the Ichimoku Kijun at GBX13,179 now also acting as resistance. Momentum indicators are mixed: MACD and RSI suggest buy signals, while ADX, Stochastic RSI, and HMA reflect ongoing selling pressure. The CCI supports buying, Bull/Bear Power is positive with intraday buying dominance but warns of overbought conditions, and the Awesome Oscillator is neutral. An initial downside price gap of around 13% was recorded, with the price rebounding toward the daily high after a significant intraday loss. Intraday volatility is elevated at 5.81%, and conflicting oscillator readings point to heightened uncertainty.

Previously it was reported that AstraZeneca faced renewed bearish momentum following key pipeline setbacks and trial disappointments. The latest developments further reinforce this negative tone, but with volatility elevated, traders should closely monitor for a potential breakout from the current GBX11,270–GBX13,251 range as the next directional signal.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.